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Background: Recent research has revealed that targeting mitochondrial bioenergetic metabolism is a promising
chemotherapeutic strategy. Key to successful implementation of this chemotherapeutic strategy is the use of new
and improved mitochondria-targeted cationic agents that selectively inhibit energy metabolism in breast cancer
cells, while exerting little or no long-term cytotoxic effect in normal cells.
Methods: In this study, we investigated the cytotoxicity and alterations in bioenergetic metabolism induced by
mitochondria-targeted vitamin E analog (Mito-chromanol, Mito-ChM) and its acetylated ester analog (Mito-ChMAc).
Assays of cell death, colony formation, mitochondrial bioenergetic function, intracellular ATP levels, intracellular and
tissue concentrations of tested compounds, and in vivo tumor growth were performed.
Results: Both Mito-ChM and Mito-ChMAc selectively depleted intracellular ATP and caused prolonged inhibition of
ATP-linked oxygen consumption rate in breast cancer cells, but not in non-cancerous cells. These effects were
significantly augmented by inhibition of glycolysis. Mito-ChM and Mito-ChMAc exhibited anti-proliferative effects
and cytotoxicity in several breast cancer cells with different genetic background. Furthermore, Mito-ChM selectively
accumulated in tumor tissue and inhibited tumor growth in a xenograft model of human breast cancer.
Conclusions: We conclude that mitochondria-targeted small molecular weight chromanols exhibit selective
anti-proliferative effects and cytotoxicity in multiple breast cancer cells, and that esterification of the hydroxyl
group in mito-chromanols is not a critical requirement for its anti-proliferative and cytotoxic effect.
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Emerging research in cancer therapy is focused on
exploiting the biochemical differences between cancer cell
and normal cell metabolism [1,2]. A major metabolic re-
programming change that occurs in most malignant can-
cer cells is the shift in energy metabolism from oxidative
phosphorylation to aerobic glycolysis (the Warburg effect)
[3]. Strategies to selectively deplete ATP levels in tumor
cells include mitochondrial targeting of lipophilic,
delocalized cationic drugs [4]. Enhanced accumulation of* Correspondence: balarama@mcw.edu
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reproduction in any medium, provided the orcationic drugs in tumor mitochondria has been attributed
to a higher (more negative inside) mitochondrial trans-
membrane potential as compared to normal cells [5].
The current chemotherapies are often associated with
significant morbidity and enhanced toxic side effects.
Many of the chemotherapeutic drugs are potently cyto-
toxic to neoplastic and normal cells, although newer
targeted therapies developed against specific cancer phe-
notypes may potentially increase efficacy and decrease
toxic side effects [6]. A major objective in cancer chemo-
therapy is to enhance tumor cell cytotoxicity without
exerting undue cytotoxicity in normal cells. Ongoing ef-
forts in our and other laboratories include development
of cationic drugs containing triphenylphosphonium cationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ring compound (e.g., Mito-Q wherein TPP+ is conjugated
to Co-Q) that preferentially target tumor cell mitochon-
dria [4,7,8].
Chromanols are a family of phenolic compounds
containing a chromanol ring system and an aliphatic side-
chain. Tocopherols (T) and tocotrienols (TT), a group of
structurally related isomeric compounds (α-, β-, γ- and
δ-T and TT) consist of a chromanol ring and a 16-carbon
side chain. A few of these compounds (α-T or Vit-E, γ-T
and γ-TT) are present in the human diet. Isomers of T
and TT exhibit cancer preventive, anti-proliferative and
pro-apoptotic antitumor activity differently in xenograft
tumor models [9-11]. The exact mechanisms by which
these agents inhibit tumorigenesis and tumor progression
remain unknown; however, various models have been
put forth, ranging from their antioxidant and anti-
inflammatory effects to altered redox-signaling [12,13].
Mito-chromanol (Mito-ChM) and Mito-chromanol ace-
tate (Mito-ChMAc) are synthetic compounds containing a
naturally occurring chromanol ring system conjugated to
an alkyl TPP+ via a side chain carbon-carbon linker
sequence (Additional file 1: Figure S1). Mito-chromanol
(Mito-ChM) was prepared by hydrolyzing Mito-
chromanol acetate (Mito-ChMAc) (Additional file 1:
Figure S1).
Recently, investigators employed a series of “redox-si-
lent” vitamin-E analogs with the phenolic hydroxyl
group replaced by a succinate moiety (α-tocopheryl suc-
cinate; α-TOS and mito-α-tocopheryl succinate, Mito-
VES) and showed their antiproliferative effects in cancer
cells [14,15]. Using spin-trapping measurements, in-
creased levels of hydroxyl radical spin adducts were
detected in cancer cells treated with these esterified ana-
logs [14]. The investigators concluded that succinylation
of the hydroxyl group was responsible for enhanced for-
mation of reactive oxygen species (ROS) and cytotoxicity
in cancer cells treated with α-TOS and Mito-VES
[14-16]. However, it remained unclear whether modifi-
cation of the phenolic hydroxyl group is a critical
requirement for the observed antitumor potential
of these agents. As part of our continuing efforts
to understand the chemotherapeutic mechanism of
mitochondria-targeted cationic drugs, we decided to
reinvestigate this problem because of the potential sig-
nificance of mitochondria-targeting small molecules in
cancer therapy [17].
To our knowledge, there exists very little information
pertaining to alteration in metabolism or bioenergetics
in tumor cells treated with chromanols, mitochondria-
targeted chromanols or analogs. As chromanols are
active components of naturally occurring antioxidants
(e.g., Vitamin-E and tocotrienols), we surmised that it is
critically important to understand the changes in breastcancer cell energy metabolism induced by mitochondria
targeted chromanols (Additional file 1: Figure S1). Here
we report that mitochondria-targeted small-molecular
weight chromanol and its acetate ester analog (Mito-
ChM and Mito-ChMAc in Additional file 1: Figure S1)
selectively promote cell death in nine breast cancer cell
lines, but spares non-tumorigenic breast epithelial MCF-
10A cells. Mito-ChM decreases intracellular ATP and
inhibits proliferation of breast cancer cells. These effects




Mito-chromanol (Mito-ChM) and Mito-chromanol
acetate (Mito-ChMAc) were synthesized using a modi-
fication of previously published procedures [18] (see
Additional file 1: Figure S1 for chemical structures
and Additional file 2: Supplementary methods). 2-
deoxyglucose (2-DG), methyl triphenylphosphonium
(Me-TPP+) and α-tocopherol (α-Toc) were purchased
from Sigma-Aldrich. D-luciferin sodium salt was
obtained from Caliper Life Sciences, Inc.
Cell culture
The breast cancer cell lines MCF-7 [estrogen receptor
positive (ER+) and human epidermal growth factor recep-
tor 2 negative (HER2-)], T47D (ER+ and HER2-), MDA-
MB-231 (ER−, and HER2-), SK-BR-3 (ER- and HER2+),
MDA- MB-453 (ER- and HER2+) and MCF-10A (ER- and
HER2-) [19] were acquired in the last three years from
the American Type Culture Collection, where they are
regularly authenticated. MDA-MB-231-Brain (brain-
seeking) were acquired in the last two years from the
National Cancer Institute, where they are regularly au-
thenticated [MDA-MB-231-Brain cells were obtained
from the NCI (Dr. Patricia Steeg) and were originally
from Dr. Yoneda at UTSW]. Tissue specific, MDA-
MB-231-Bone (bone-seeking) and MDA-MB-231-Lung
(lung-seeking) cells were the kind gift of Dr. Massague
(Memorial Sloan Kettering, New York, NY) as defined
previously [20,21]. Cells were stored in liquid nitrogen
and used within six months after thawing. Cell lines
were grown at 37°C in 5% CO2. MCF-7 cells were
maintained in MEM-α (Invitrogen) containing 10% fetal
bovine serum, bovine insulin (10 μg/ml), penicillin
(100 U/ml) and streptomycin (100 μg/ml). MCF-
10A cells were cultured in DMEM/F12 media (1:1)
(Invitrogen) supplemented with 5% horse serum, bovine
insulin (10 μg/ml), epidermal growth factor (20 ng/ml),
cholera toxin (100 ng/ml), and hydrocortisone (0.5 μg/ml),
penicillin (100 U/ml) and streptomycin (100 μg/ml).
MDA-MB-453, MDA-MB-231, MDA-MB-231-Brain,
MDA-MB-231-Bone and MDA-MB-231-Lung cells were
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(100 U/ml) and streptomycin (100 μg/ml). T47D cells
were cultured in RPMI 1640, 10% fetal bovine serum, peni-
cillin (100 U/ml) and streptomycin (100 μg/ml). SK-BR-3
cells were cultured in McCoys 5A, 10% fetal bovine serum,
penicillin (100 U/ml) and streptomycin (100 μg/ml). The
MDA-MB-231-luc cell line stably transfected with lucifer-
ase was cultured under the same conditions as the MDA-
MB-231 cells described above and were recently described
in detail [22]. They were regularly assessed for standard
growth characteristics, and tumorigenicity in nude mice.
Cell death and clonogenic assays
Breast cancer cells and MCF-10A cells seeded at 1 × 104
per well in 96-well plates were treated with Mito-ChM
or Mito-ChMAc for 24 h, and dead cells were monitored
in the presence of 200 nM Sytox Green (Invitrogen).
The Sytox method labels the nuclei of dead cells yielding
green fluorescence. Fluorescence intensities from the
dead cells in 96-well plate were acquired in real time
every 5 min for first 4 h, then every 15 min after 4 h
using a plate reader (BMG Labtech, Inc.) equipped with
atmosphere controller set at 37°C and 5% CO2:95% air
using a fluorescence detection with 485 nm excitation
and 535 nm emission. To measure the total cell number,
all of the samples in each treatment group were perme-
abilized by adding Triton X 100 (0.065%) in the presence
of Sytox Green for 3 h, and maximal fluorescence inten-
sities were taken as 100%. Data are represented as a per-
centage of dead cells after normalization to total cell
number for each group.
The IncuCyte™ Live-Cell Imaging system was used for
kinetic monitoring of cytotoxicity as determined by
Sytox Green staining at regular cell culture condition
[23]. Additionally, phase-contrast and fluorescent images
were automatically collected for each time point to de-
termine morphological cell changes.
For clonogenic assay, MCF-7, MDA-MB-231 and
MCF-10A cells were seeded at 300 cells per dish in 6 cm
diameter cell culture dishes and treated with Mito-ChM
for 4 h. After 7–14 days, the number of colonies formed
was determined. The cell survival fractions were calcu-
lated according to a published protocol [24].
Extracellular flux assay
To determine the mitochondrial and glycolytic function
of MCF-7 and MCF-10A cells treated with Mito-ChM,
we used the bioenergetic function assay previously de-
scribed [4]. After seeding and treatment as indicated,
MCF-7 cells and MCF-10A cells were washed with
complete media and either assayed immediately, or
returned to a CO2 incubator for 24, 48 or 72 h. The cells
were then washed with unbuffered media as previously
described [4]. Five baseline oxygen consumption rate(OCR) and extracellular acidification rate (ECAR)
measurements were then recorded before injecting
oligomycin (1 μg/ml) to inhibit ATP synthase, 2,4-dini-
trophenol (DNP, 50 μM) to uncouple the mitochondria
and yield maximal OCR, and rotenone (Rot, 1 μM) and
antimycin A (AA, 10 μM) to prevent mitochondrial oxy-
gen consumption through inhibition of Complex I and
Complex III, respectively. From these measurements,
indices of mitochondrial function were determined as
previously described [25,26].
Intracellular ATP measurements
After seeding and treatment as indicated, MCF-7, MDA-
MB-231, and MCF-10A cells were washed with complete
media and either assayed immediately, or returned to a
CO2 incubator for 24, 48 or 72 h. Intracellular ATP
levels were determined in cell lysates using a luciferase-
based assay per manufacturer’s instructions (Sigma
Aldrich). Results were normalized to the total protein
level in cell lysate, as determined by the Bradford
method (Bio-Rad).
Measurement of intracellular concentrations of Mito-ChM
and Mito-ChMAc
After incubation, cells were washed twice with ice-cold
DPBS and harvested. The cell pellet was immediately
frozen in liquid nitrogen and stored at −80°C. For the
extraction, the pellet was homogenized in DPBS and
extracted twice with dichloromethane:methanol (2:1)
mixture containing 2 mM butylated hydroxytoluene
(BHT) to prevent oxidation of the chromanol ring. The
organic layers were combined and dried using SpeedVac.
The dry residue was dissolved in ice-cold methanol
containing 2 mM BHT and taken for HPLC analysis. A
similar protocol was used for extraction of Mito-ChM
from tissue samples from the in vivo xenograft expe-
riments, but tissue homogenization and extraction
were performed with the use of Omni Bead Ruptor 24
homogenizer (Omni International).
HPLC with electrochemical detection was used to de-
tect and quantify Mito-ChM and α-tocopherol. The
HPLC system (ESA) and was equipped with CoulArray
detector containing eight coulometric cells connected in
a series. Analytes were separated on a Synergi Polar RP
column (Phenomenex, 250 mm × 4.6 mm, 4 μm) using a
mobile phase containing 25 mM lithium acetate
(pH 4.7) in 95% methanol. The isocratic elution with the
flow rate of 1.3 ml/min was used. The voltages applied
to the coulometric cells were as follows: 0, 200, 300, 600,
650, 700, 750 and 800 mV. At concentrations 10 μM
and lower, the dominant peak was observed at 300 mV;
at higher concentrations the dominant peak was ob-
served at 600 mV. For quantitative analyses, the areas
of peaks detected at potentials 200 – 650 mV were
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concentration.
The simultaneous quantification of Mito-ChM and
Mito-ChMAc in the extracts was performed using the
UHPLC system (Shimadzu Nexera) coupled to an MS/
MS detector (Shimadzu 8030). The following parameters
of the MS detector were used: ionization mode:
electrospray (ESI); nebulizing gas (N2) flow: 2 l/min;
drying gas (N2) flow: 15 l/min; desolvation line
temperature: 250°C; heat block temperature: 400°C; col-
lision gas: Ar. The compounds were separated on a
Kinetex PhenylHexyl column (Phenomenex, 50 mm ×
2.1 mm, 1.7 μm) thermostated at 40°C, using a mobile
phase containing 0.1% formic acid in water/acetonitrile
mixture with a gradient of acetonitrile from 50% to 80%
over 6 min. The flow rate was set at 0.4 ml/min. The
detector was set to continuously scan the eluate in the
positive mode in the m/z range between 10 and 1000.
Additionally, for selective monitoring of Mito-ChM and
Mito-ChMAc, the multiple reaction monitoring (MRM)
transitions of 679.1→ 515.0 (for Mito-ChM) and
721.1→ 415.0 (for Mito-ChMAc) were used and the
corresponding peak areas were used for quantitative
analysis.
Xenograft experiments
All protocols were approved by the Medical College of
Wisconsin Institutional Animal Care and Use Commit-
tee. MDA-MB-231-luc cells (5 × 105 cells in 200 μl of a
mixture of 1:1 PBS/Matrigel (BD Biosciences) were
injected into the right mammary fat-pad of 8-week-old
female SHO mice (Charles Rivers). Tumor establishment
and growth were monitored 18–24 h after receiving
Mito-ChM by injecting D-luciferin as per manufacturer’s
instructions (Caliper Life Sciences) and detecting
bioluminescence using the Lumina IVIS-100 In Vivo
Imaging System (Xenogen Corp.) [22]. The light inten-
sities emitted from regions of interest were expressed as
total flux (photons/second). Two days after injecting the
cells, mice were imaged to verify tumor establishment.
Mice were then orally gavaged with either water
(control, shared group as in Reference [4]) or Mito-ChM
(60 mg/kg) five times/wk (Monday through Friday).
After 4 weeks of treatment and 48 h after receiving last
administration the mice were sacrificed, and the tumor,
kidney, heart and liver were removed. Half of tissue
samples were snap-frozen in liquid nitrogen and stored
at −80°C for Mito-ChM extraction, and the other half
was formalin fixed and paraffin embedded for hematoxylin
and eosin (H&E) staining.
Statistics
All results are expressed as mean±SEM. Comparisons
among groups of data were made using a one-wayANOVA with Tukey post hoc analysis. P value of less
than 0.05 was considered to be statistically significant.
Results
Cytotoxic and anti-proliferative effects of Mito-ChM and
Mito-ChMAc in breast cancer and non-cancerous cells
The dose-dependent cytotoxicity of Mito-ChM or
Mito-ChMAc in nine breast cancer and non-cancerous
MCF-10A cells was monitored for 24 h (Figure 1). Both
Mito-ChM and Mito-ChMAc caused a dramatic increase
in cytotoxicity in all nine breast cancer cell lines tested
(Figure 1 and Additional file 1: Figure S2) but not in
MCF-10A cells (Figure 1A and Additional file 1: Figure S2).
The EC50 values (concentration inducing 50% of cell
death) for Mito-ChM after a 4 h treatment in all cell lines
tested are shown in Figure 1B. In eight out of nine breast
cancer cell lines, the EC50 values measured for Mito-ChM
were below 10 μM. The acetate ester of Mito-ChM
exhibited similar but slightly higher EC50 values, as shown
in Additional file 1: Figure S2B. With MCF-7 cells, the
estimated EC50 for Mito-ChM at 4 h was 20 μM, while in
MCF-10A we did not observe any toxicity under these
conditions. The relatively higher EC50 value in MCF-7
cells can be ra tionalized by a delayed response to Mito-
ChM, as shown in Figure 1A. Notably, the EC50 values
of Mito-ChM in MCF-7 cells measured to be ca. 10.4 ±
0.2 μM and 7.8 ± 0.4 μM for a 12 and 24 h incubation
period, respectively. The EC50 values for Mito-ChMAc
under the same conditions were 11.9 ± 0.4 μM (12 h) and
8.8 ± 0.1 μM (24 h) (Additional file 1: Figure S2). In con-
trast, the EC50 values for these agents in MCF-10A cells
were much greater than 20 μM (Figure 1A and Additional
file 1: Figure S2) even after a 24 h incubation.
We further confirmed these results by monitoring in
real time the cytotoxicity of Mito-ChM using IncuCyte
(Additional file 1: Figure S3) which enabled continuous
monitoring of Sytox fluorescence intensity (Additional
file 3: Figure S3B) and collecting of the phase contrast
and fluorescence images of the cells. The corresponding
confocal fluorescence images of MCF-7 cells (marked 1–4,
top) and MCF-10A cells (marked 5–8, bottom) treated
with 20 μM of Mito-ChM are shown in Additional file 1:
Figure S3. Results obtained using the IncuCyte are consis-
tent with the cytotoxicity results obtained with the plate
reader (Figure 1A). Notably, similar effects of Mito-ChM
on cell death for 24 h treatment were observed using the
endpoint Sytox Green assay, implying that incubation with
Sytox probe had no adverse effect (data not shown). Incuba-
tion with α-Toc (up to 20 μM) (Additional file 1: Figure S1)
in the presence and absence of Me-TPP+ (up to 20 μM)
did not significantly increase cytotoxicity in either MCF-7
or MCF-10A cells, even after a 24 h treatment (data not
shown). These results suggest that TPP+ conjugation to a
chromanol moiety via the carbon-carbon linker side chain
Figure 1 The cytotoxic effect of Mito-ChM in breast cancer and non-cancerous cells. Nine different breast cancer cells and MCF-10A cells
were treated with Mito-ChM at the indicated concentrations (0.5-20 μM) for 24 h, and cell death was monitored in real time by Sytox Green
staining. Data shown are the means ± SEM for n = 4. Real time cell death curves were plotted in panel A for MCF-7 (left), MDA-MB-231 (middle)
and MCF-10A cells (right). Panel B shows the titration of breast cancer and non-cancerous cells with Mito-ChM, and the extent of cell death
observed after 4 h treatment is plotted against Mito-ChM concentration. Solid lines represent the fitting curves used for determination of the
EC50 values, indicated in each panel.
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proliferative effects in breast cancer cells. These results
also indicate that even the acetate ester form of Mito-
ChM (i.e., Mito-ChMAc) is equally cytotoxic in breast
cancer cells.
We used a clonogenic assay to monitor the anti-
proliferative effects of Mito-ChM. As shown in Figure 2A,
there was a dramatic decrease in colony formation in
MCF-7 and MDA-MB-231 cells, as compared to MCF-
10A cells, when treated with Mito-ChM (1–10 μM) for
4 h. Figure 2B shows the calculated survival fractions of
MCF-7, MDA-MB-231 and MCF-10A cells. Mito-ChM
significantly decreased the survival fraction in MCF-7 and
MDA-MB-231 cells as compared to MCF-10A cells. Not-
ably, the colony formation data indicate that a 4 h treat-
ment with 3 μM Mito-ChM was sufficient to induce
significant anti-proliferative effects in both MCF-7 and
MDA-MB-231 cells without noticeable cell death underthose conditions (Figure 1A). Taken together, we conclude
that a 4 h treatment with 3 μM Mito-ChM was sufficient
to inhibit cancer cell growth, without directly causing cell
death at this time point.
Effects of Mito-ChM on mitochondrial bioenergetic
function in MCF-7 and MCF-10A cells
To better understand the differential cytotoxic effects of
Mito-ChM, we monitored the changes in bioenergetic
function with time in MCF-7 and MCF-10A cells using
the XF24 extracellular flux analyzer. The experimental
protocol for this experiment is shown in Figure 3A. Both
cell lines were treated with Mito-ChM (1–10 μM) for
4 h, washed and returned to fresh culture media. The
oxygen consumption rate (OCR) and extracellular aci-
dification rate (ECAR) were measured immediately and
after 24, 48, and 72 h (Figure 3B,C,D, and E; left;
Additional file 3: Table S1). The effects of mitochondrial
Figure 2 Effects of Mito-ChM on colony formation in MCF-7,
MDA-MB-231 and MCF-10A cells. (A) MCF-7, MDA-MB-231 and
MCF-10A cells were treated with Mito-ChM (1–10 μM) for 4 h and
the colonies formed were counted. (B) The survival fraction was
calculated under the same conditions as in (A). Data shown
represent the mean ± SEM. *, P < 0.05, **, P < 0.01 (n = 6) comparing
MCF-7 and MDA-MB-231 with MCF-10A under the same
treatment conditions.
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rotenone (Rot) and antimycin A (AA) in MCF-7 and
MCF-10A cells were determined (Figure 3B,C,D, and E;
right). The use of these metabolic modulators allows de-
termination of multiple parameters of the mitochondrial
function, as described previously [4,23,24]. As can be
seen, the inhibition of OCR and mitochondrial function
was persistent even at 72 h after removal of Mito-ChM
in MCF-7 cells, but not in MCF-10A cells (Figure 3E).
The quantitative changes in bioenergetic function
(ECAR, ATP-linked OCR and maximal OCR) in MCF-7
and MCF-10A cells following treatment with Mito-ChM
and washout with time are shown in Additional file 3:
Table S1. The striking finding is the dramatic recovery
in ATP-linked OCR from Mito-ChM treatment in MCF-
10A but not in MCF-7 cells at 48 to 72 h after washout
(Additional file 3: Table S1). Plausible reasons for this se-
lectivity are discussed below.Effects of Mito-ChM on intracellular ATP levels in MCF-7,
MDA-MB-231 and MCF-10A cells
The intracellular ATP levels in MCF-7, MDA-MB-231
and MCF-10A cells treated with different concentrations
of Mito-ChM (1–20 μM) for 1–8 h, immediately and
after a 24–72 h washout period, were measured using a
luciferase-based assay [22]. The absolute values of intra-
cellular ATP levels (after normalization to total protein
content) in MCF-7, MDA-MB-231 and MCF-10A cells
following treatment with Mito-ChM are shown in
Additional file 3: Tables S2, S3 and S4. Figure 4 (A-D)
shows a heat map representation of intracellular ATP
levels in these cells (colored areas from brown to purple
indicate a progressive decrease in ATP from 100% to
0%). As shown, Mito-ChM induced a decrease in intra-
cellular ATP levels in MCF-7 and MDA-MB-231 but not
in MCF-10A cells, even after a 72 h washout in a time-
and concentration-dependent manner. For example, a
4 h treatment with Mito-ChM (15 μM) followed by a
48 h washout decreased ATP (nmol ATP/mg protein) in
MCF-7 cells from 22.3 ± 0.6 to 3.3 ± 0.2, in MDA-MB-231
cells from 26.0 ± 0.9 to 7.1 ± 1.3 and in MCF-10A cells
from 25.6 ± 0.4 to 21.9 ± 1.2. These results suggest that
Mito-ChM treatment strongly inhibits intracellular energy
metabolism in MCF-7 and MDA-MB-231 but not in
MCF-10A cells.
Enhanced sequestration of Mito-ChM in MCF-7
and MDA-MB-231 cells
We used HPLC with electrochemical detection (HPLC-EC)
to measure the intracellular concentrations of Mito-ChM
in MCF-7, MDA-MB-231 and MCF-10A cells. Treatment
of MCF-7 and MCF-10A cells with Mito-ChM for 4 h
resulted in the accumulation of Mito-ChM in both cell
lines, but their levels in MCF-7 cells were 2.7-fold higher
than in MCF-10A cells (Figure 5A). Incubation of the
same cells for an additional 24 h in Mito-ChM-free media
caused a more pronounced difference in intracellular
levels of Mito-ChM in MCF-7 and MCF-10A cells
(Figure 5B). Incubation with 1 μM of Mito-ChM for 48 h
caused a 6-fold difference in intracellular accumulation
of Mito-ChM (Figure 5C). Similar experiments were
performed using Mito-ChMAc. Mito-ChMAc underwent
intracellular hydrolysis, forming mostly Mito-ChM in
both cell lines after a 4 h incubation (Figure 5D). This was
further confirmed by LC-MS/MS equipped with multiple
reaction-monitoring capabilities. Incubation of both
MCF-7 and MCF-10A cells with 10 μM Mito-ChMAc
caused significantly higher levels of Mito-ChM (ca. 85% of
total amount) as compared to Mito-ChMAc (ca. 15%),
with no apparent differences in hydrolytic activities
between both cell lines (Figure 5E). Consistent with
Figure 5A, the intracellular concentration of Mito-ChM
was significantly higher in MCF-7 cells as compared to
Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Effects of Mito-ChM on basal OCR and bioenergetics functions in MCF-7 and MCF-10A cells. (A) Experimental protocol for
bioenergetic functional assay. To determine the mitochondrial and glycolytic function of MCF-7 and MCF-10A cells in response to Mito-ChM
(1–10 μM), we used the bioenergetic functional assay previously described (4,25). After seeding and treatment, MCF-7 cells and MCF-10A cells
were subsequently washed with complete media (MEM-α for MCF-7 and DMEM/F12 for MCF-10A) and either assayed immediately, or returned to
a 37°C incubator for 24, 48, or 72 h. The relative time of treatment and post-treatment incubation that corresponds to the appropriate figures is
indicated. (B) MCF-7 and MCF-10A cells were assayed for OCR immediately after treatment with Mito-ChM (1–10 μM) for 4 h, (C) after incubation
without Mito-ChM for an additional 24 h, (D) after additional incubation without Mito-ChM for 48 h, and (E) after additional incubation without
Mito-ChM for 72 h.
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Similar to MCF-7 cells, enhanced accumulation of
Mito-ChM was also observed in MDA-MB-231 cells
(Figure 5F).
Effects of Mito-ChM on tumor growth: Breast cancer
xenograft model
We investigated the ability of Mito-ChM to exert che-
motherapeutic effects in an in vivo breast tumor model.
First, we tested the accumulation of Mito-ChM in tumor
tissue, as compared with selected organs, including
heart, liver and kidney (Figure 6A and B). Mito-ChM
accumulated selectively in tumor and kidney, but not in
heart or liver tissue, as measured 48 h after receiving the
last dose of Mito-ChM. Administration of Mito-ChM
led to a 45% decrease in the bioluminescence signal in-
tensity (total flux) as compared to the control mice after
4 weeks of treatment (Figure 6C and D). Furthermore,
this treatment significantly diminished tumor weight
(Figure 6D) by 30% as compared to the control mice,
without causing significant changes in kidney, liver and
heart weights or other major morphological changes
(as determined by H&E staining in Additional file 1:
Figure S4 and Additional file 3: Table S5).
Antiglycolytic agents synergistically enhance the
anti-proliferative and cytotoxic effects of Mito-ChM
and Mito-ChMAc
At higher concentrations (= 10 μM), Mito-ChM inhibits
both OCR and ECAR and exerts selective toxicity to
MCF-7 cells (Figure 3 and Additional file 3: Table S1).
We decided to investigate whether dual targeting with
mitochondrial and glycolytic inhibitors would enhance the
efficacy of Mito-ChM at lower concentrations (≈ 1 μM).
To this end, cells were treated with Mito-ChM combined
with glycolytic inhibitor, 2-deoxyglucose (2-DG). As
shown in Figure 7A, there was a substantial decrease in
colony formation in MCF-7 cells when treated with 2-DG
in the presence of 1 μM Mito-ChM. Mito-ChM more
potently decreased the survival fraction in MCF-7 cells as
compared to MCF-10A cells in the presence of 2-DG
(Figure 7B). The combined treatment with 2-DG and
1 μM Mito-ChM or 1 μM Mito-ChMAc also caused a
dramatic increase in cytotoxicity in MCF-7 as comparedto MCF-10A cells (Figure 7C and inset; Figure 7D and
inset). Live cell imaging and kinetic monitoring of cyto-
toxicity using the IncuCyte system also revealed similar
results (Additional file 1: Figure S5).
Discussion
In this study we report the use of relatively nontoxic
cationic mitochondria-targeted synthetic compounds
containing a naturally-occurring chromanol ring system
to selectively inhibit breast cancer cell energy metabo-
lism and promote anti-proliferative effects and cyto-
toxicity. These effects were synergistically enhanced in
combination with anti-glycolytic agents (e.g., 2-DG). In
this study we also report that both Mito-ChM and its
acetate ester analog, Mito-ChMAc, are nearly equipotent
and exert selective toxicity in breast cancer cells.
Mitochondria targeting of cationic compounds in cancer
therapy
Lipophilic, delocalized cationic compounds were used to
target tumor mitochondria because of a higher (more
negative inside) mitochondrial transmembrane potential
in tumor cells as compared to normal cells [27,28].
Rhodamine-123 (Rh-123) is a lipophilic, cationic fluores-
cent dye that was used as an indicator of the transmem-
brane potential. Rh-123 was shown to be retained longer
(2–3 days) in the mitochondria of tumor-derived cells
than in mitochondria of normal epithelial-derived cells
[29]. The increased uptake and retention of Rh-123 in
cancer cells correlated well with its selective and
enhanced toxicity in cancer cells. However, Rh-123
inhibited cancer cell growth at much higher concen-
trations than did Mito-ChM. Rh-123 treatment alone
(up to 100 μM for 6 h treatment) did not cause signifi-
cant intracellular ATP depletion in MCF-7 cells; how-
ever, the combined treatment of Rh-123 (30 μM) and
2-DG induced a rapid loss of ATP in MCF-7 cells (data
not shown). In contrast, Mito-ChM or Mito-ChMAc
alone induced ATP depletion in MCF-7 and MDA-MB-
231 cells. Interestingly, Mito-ChM did not significantly
deplete intracellular ATP levels in non-cancerous MCF-
10A cells, even though it inhibited mitochondrial respir-
ation upon direct treatment (Figure 3B). This may be
interpreted in terms of the differences in the potential to
Figure 4 The effect of Mito-ChM on intracellular ATP levels in MCF-7, MDA-MB-231 and MCF-10A cells. (A) The MCF-7, MDA-MB-231 and
MCF-10A cells seeded in 96-well plates were treated with Mito-ChM (1–20 μM) as indicated for 1–8 h. After treatment, cells were washed with
complete media and either assayed immediately, or returned to cell culture incubator for (B) 24 h, (C) 48 h, or (D) 72 h. Intracellular ATP levels
were measured using a luciferase-based assay. Data are represented as a percentage of control (non-treated) cells after normalization to total
cellular protein for each well. The calculated absolute values of ATP (nmol ATP/mg protein) for MCF-7, MDA-MB-231 and MCF-10A cells are
shown in Additional file 3: Tables S2, S3 and S4, respectively.
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Figure 5 Intracellular accumulation of Mito-ChM in MCF-7, MDA-MB-231 and MCF-10A cells. (A) HPLC-EC chromatograms (dominant
channels) of the mixture of standards (100 μM) of α-tocopherol and Mito-ChM, and of extracts from cells treated for 4 h with 10 μM Mito-ChM
(left panel). Quantitative data on intracellular concentration of Mito-ChM after normalization to protein content (right panel). (B) Same as in panel
A, but after a 4 h treatment with 10 μM Mito-ChM, medium was changed and cells incubated further for another 24 h in culture medium in the
absence of Mito-ChM. Chromatogram of standards represents a mixture of α-tocopherol and Mito-ChM (10 μM each). (C) Same as in panel A, but
cells were treated for 48 h with 1 μM Mito-ChM. Chromatogram of standards represents a mixture of α-tocopherol and Mito-ChM (1 μM each).
(D) Same as in panel A, but cells were treated for 4 h with 10 μM Mito-ChMAc. (E) HPLC-MS/MS chromatograms [MRM transitions: 679.1→ 515.0
for Mito-ChM (upper traces) and 721.1→ 415.0 for Mito-ChMAc (lower traces)] of the mixture of standards (100 μM) of Mito-ChM and Mito-ChMAc,
and of extracts from cells treated for 4 h with 10 μM Mito-ChMAc (left panel). Quantitative data on intracellular concentrations of Mito-ChM and
MitoChMAc after normalization to protein content (right panel). (F) Intracellular levels of Mito-ChM in MDA-MB-231 cells incubated for 2 and 4 h
with 10 μM Mito-ChM or Mito-ChMAc (left panel). Right panel shows similar data, but after 4 h incubation with the compounds, cells were
incubated for 24 h in culture medium alone.
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ATP production by mitochondrial respiration) in cancer-
ous MCF-7 cells and non-cancerous MCF-10A cells. We
have recently shown that MCF-10A cells have signifi-
cantly higher glycolytic potential, as compared to MCF-7
cells [4]. Other mechanisms of selective retention of
ATP upon direct treatment with Mito-ChM in non-
cancerous MCF-10A cells cannot be excluded.
Selective uptake and retention of TPP+-based mito-
chondria targeted drugs in breast cancer cells is facili-
tated by a combination of several factors, including the
lipophilicity of the delocalized cation, the ability to
optimize the length of the linking carbon chain, and
mitochondrial membrane potential. Mito-ChM and
Mito-ChMAc are sequestered into cancer cells to a
greater extent as compared to normal cells, and in
tumor and kidney, as compared to heart or liver in
treated mice. A major reason for this selective chemo-
therapeutic effect is attributed to the preferential andprolonged accumulation of these compounds in breast
cancer cells. In addition, mito-chromanols are exquis-
itely more selective in inhibiting breast cancer cell
growth as compared to other mitochondria-targeted
drugs (e.g., Mito-CP and Mito-Q). Both Mito-ChM (with
an antioxidant phenolic hydroxyl group intact) and
Mito-ChMAc (lacking a free hydroxyl group) are equally
potent in breast cancer cells. The cytotoxic activity of
Mito-ChMAc may be attributed to the hydrolyzed form
(Mito-ChM), as we observed significant hydrolysis of the
compound both in breast cancer and non-cancerous
cells. This finding calls into question the critical ne-
cessity for blocking the phenolic hydroxyl group by the
succinate moiety in previous studies reporting the antican-
cer activity of mitochondria-targeted vitamin E succinate
(Mito-VES) [15].
In this context, it is important to highlight the safety
profile of Mito-Q10, a related mitochondria-targeted
antioxidant, in animals and in humans [30]. Although,
Figure 6 Tissue accumulation and tumor growth inhibitory activity of Mito-ChM in in vivo MDA-MB-231-luc xenograft model.
(A) HPLC-MS/MS chromatograms (MRM transition: 679.1→ 515.0) of the Mito-ChM standard (1 μM), and of indicated tissue extracts from MDA-MB
-231-luc tumor xenograft mice treated with Mito-ChM. Quantitative data on concentrations of Mito-ChM after normalization to tissue wet weight are
shown in panel B. Tumor growth was determined by both bioluminescence signal intensity and tumor wet weight after 4 weeks of treatment.
Representative bioluminescent images are show in (C). Quantitative data were plotted in panel D on bioluminescence signal intensity (left) and wet
tumor weight (right). Data are represented as a percentage of control mice, mean ± SEM (n = 10, control group and n = 9, Mito-ChM treated group).
*, P < 0.05 vs. control group.
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generate detectable levels of reactive oxygen species,
prolonged treatment with this drug did not increase oxi-
dative damage or ROS levels in vivo [30]. As discussed
in a recent review article [30], measurement of ROS as a
minor pro-oxidant reaction in vitro does not mean that
ROS generation from these drugs is a major mechanism
of cancer cell death.
Energy metabolism, metabolic reprogramming, and
mitochondrial function in cancer therapy
Recent research revealed a regulatory link between glucose
metabolism and expression of oncogenes and tumor sup-
pressors in cancer cells [31-33]. Previous work has revealed
that cancer-promoting oncogenes and hypoxia-inducible
factor (HIF-1α) induce a glycolytic shift [34]. Activation of
oncogenic signaling pathways involving PI3K/AkT/mTOR,
c-Myc, Src, and Ras results in an enhanced glucose uptake
and glycolytic activity, mimicking the Warburg phenotype
in cancer cells [35,36]. Suppression of mitochondrial en-
ergy metabolism in breast cancer cells would potentially
counteract the aerobic glycolysis advantage acquiredthrough metabolic reprogramming. Targeting of both
mitochondrial bioenergetic function and the glycolytic
pathway is a promising chemotherapeutic strategy [31,37].
However, the key to successful cancer therapy remains to
be the selectivity [4,38]. In this regard, Mito-ChM and
analogs offer a unique advantage. Coupling energy
restriction-mimetic agents (e.g., thiazolidinediones) with
mitochondria-targeted agents may be a very effective
small-molecule based anticancer therapy [39].
Chemotherapy and ATP depletion
The present results indicate that Mito-ChM or Mito-
ChMAc (1–20 μM) decreased intracellular ATP levels in
a concentration- and time-dependent manner (Figure 4).
The intracellular levels of Mito-ChM could decrease via
the pumping mechanism of p-glycoprotein or MDR-1, a
multidrug transporter [40]. However, as ATP is required
for the pumping mechanism of p-glycoprotein, Mito-
ChM-induced depletion of ATP could hinder the pump
activity, thereby accumulating the cationic drug. Thus, a
key advantage of using mito-chromanols in combination
with a chemotherapeutic drug that induces multi-drug
Figure 7 Synergistic cytotoxicity and anti-proliferative effects of Mito-ChM and 2-DG. (A) Representative pictures of the colonies formed.
MCF-7 and MCF-10A cells were treated with 2-DG only (upper) or 2-DG in the presence of Mito-ChM (1 μM) (lower) for 4 h and the colonies
formed were counted. (B) The survival fraction was calculated under the same conditions as in (A). (C,D) Cytotoxic effects of the combination of
Mito-ChM and 2-DG. MCF-7 (main panels) and MCF-10A (inserts) cells were treated with 2-DG alone (at the indicated concentrations), 2-DG in the
presence of 1 μM Mito-ChM (C) or 1 μM Mito-ChMAc (D) for 24 h and cell death was monitored in real time by Sytox Green staining. Data
shown are the mean ± SEM. n = 4-6.
Cheng et al. BMC Cancer 2013, 13:285 Page 12 of 14
http://www.biomedcentral.com/1471-2407/13/285resistance through elevated p-glycoprotein expression
might be the depletion of intracellular ATP. Intracellular
ATP levels reportedly regulate chemoresistance in colon
cancer cells [41]. A recent report indicates that the use
of mitochondrially targeted drugs could counteract
ABCA1-dependent resistance of the lung carcinoma
cells [42].
It is well known that redox-based chemotherapeutics
induce depletion of intracellular ATP levels via increased
oxidative stress [43]. Unfortunately, these drugs also
cause toxic side effects through oxidative mechanism
of activation [44]. In this study, we show that
mitochondria-targeted cationic drugs deplete intracellu-
lar ATP, not through redox activation mechanism, but
through selective inhibition of ATP-linked respiration in
tumor cells. As shown in Figure 4, this inhibitory effectis prolonged and permanent in breast cancer cells but
not in control, noncancerous cells.
Mitochondria-targeted cationic antioxidants: maximizing
therapeutic index
The added value of mitochondria targeted cationic drugs
attached to a functionally-active antioxidant group is that
they will afford increased cytoprotection in normal cells
through inhibition of mitochondrial oxidative damage
caused by conventional chemotherapy. The therapeutic
potential of mitochondria targeting in cancer therapy
enhances the overall therapeutic index. Mitochondria-
targeted vitamin E analog inhibits oxidative stress in
normal cells [18,45]. Previous studies have shown that
mitochondria-targeted drugs (Mito-Q and Mito-CP) ef-
fectively mitigated cardiotoxic and nephrotoxic side
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cis-platin [46,47].
Several attempts have been made to make use of the
Warburg phenotypic trait (aerobic glycolysis) in cancer
chemotherapy [48,49]. However, this approach has not
yielded a viable chemotherapeutic strategy because of the
systemic toxicity of the high concentrations of 2-DG typ-
ically used in these studies [31]. The combined inhibition
of glycolysis and mitochondrial function allows the use of
much lower concentrations of 2-DG. The present studies
suggest that a dual targeting of relatively nontoxic mito-
chromanols and glycolytic inhibitors is a viable and gener-
alized chemotherapeutic approach. Mito-chromanols ex-
hibit considerable tumor selectivity as evidenced by a
similar EC50 value in eight different breast cancer cells
with different genetic backgrounds. The role of stromal
cells and the tumor microenvironment in general in
modulating tumour sensitivity is crucial to developing
successful anticancer therapeutics. Future studies should
focus on investigating the effect of mitochondria-targeted
small molecules on stromal cells alone and on the com-
bination of cancer cells with stromal cells.
Conclusion
We report a novel and selective chemotherapeutic strategy
using mitochondria-targeted chromanol and its acetylated
ester analog to selectively inhibit breast cancer cell energy
metabolism and proliferation and promote cytotoxicity.
For maximal therapeutic index, it is essential to use
mitochondria-targeted, TPP+-conjugated cationic drug at-
tached to a functionally active antioxidant group
(nitroxide, nitrone, chromanol, or ubiquinone).
Additional files
Additional file 1: Figure S1. Chemical structures of Mito-ChM, Mito-
ChMAc, α-Toc, Me-TPP+ and 2-deoxy-D-glucose (2-DG). Figure S2: The
cytotoxic effect of Mito-ChMAc in breast cancer and non-cancerous cells.
Nine different breast cancer cells and MCF-10A cells were treated with
Mito-ChMAc, and cell death was monitored in real time by Sytox Green
staining. Figure S3: The effect of Mito-ChM on the extent of cell death in
MCF-7 and MCF-10A cells. Cell death was monitored in real time with
IncuCyte by Sytox Green staining. The corresponding representative
fluorescence images are shown. Figure S4: Hematoxylin and eosin (H&E)
staining. Representative images of tissue collected from control and Mito-
ChM-treated mice. Figure S5: Effect of 2-DG and Mito-ChM (1 μM) on
the extent of cell death in MCF-7 and MCF-10A cells. Cell death was
monitored in real time with IncuCyte. The corresponding representative
fluorescence images are shown. Figure S6: Scheme of the multistep
synthesis of Mito-ChMAc.
Additional file 2: Supplementary methods. Supplemental text
describing synthetic protocol for Mito-ChM and Mito-ChMAc.
Additional file 3: Table S1. Effects of Mito-ChM on ECAR, ATP-linked
OCR and maximal OCR in MCF-7 and MCF-10A cells. Cells were treated with
Mito-ChM as indicated in Figure 3. The quantitative changes in bioenergetic
functional parameters following treatment at different time periods after
washout are shown. Table S2, S3 and S4: The effect of Mito-ChM on
intracellular ATP levels in MCF-7, MDA-MB-231 and MCF-10A cells,respectively. The absolute values of intracellular ATP levels (after
normalization to total protein content, nmol ATP/mg protein) in MCF-7,
MDA-MB-231 and MCF-10A cells following treatment with Mito-ChM are
shown in Table S2, S3 and S4 while as percentage data were shown in
Figure 4 as heat map figures. Table S5: Effects of Mito-ChM on body
weight and tissue weight in xenograft mouse models. The total body
weight and weights of kidney, liver and heart in control and Mito-ChM
treated mice for 4 weeks are provided.
Abbreviations
AA: Antimycin A; ATP: Adenosine-5′-triphosphate; BHT: Butylated
hydroxytoluene; 2-DG: 2-deoxyglucose; DNP: 2,4-dinitrophenol;
EC50: Concentration inducing 50% of cell death; ECAR: Extracellular
acidification rate; ER: Estrogen receptor; HER2: Human epidermal growth
factor receptor 2; H&E staining: Hematoxylin and eosin staining; HPLC-
EC: HPLC with electrochemical detection; Me-TPP+: Methyl
triphenylphosphonium; Mito-ChM: Mitochondria-targeted chromanol; Mito-
ChMAc: Mitochondria-targeted chromanol acetylated ester analog; Mito-
CP: Carboxy Proxyl conjugated to TPP+; Mito-Q: Co-enzyme Q conjugated to
TPP+; Mito-VES: Mito-α-tocopheryl succinate; MRM: Multiple reaction monitoring;
OCR: Oxygen consumption rate; Oligo: Oligomycin; Rh-123: Rhodamine-123;
ROS: Reactive oxygen species; Rot: Rotenone; T: Tocopherols; α-Toc: α-
tocopherol; α-TOS: α-tocopheryl succinate; TPP+: Triphenylphosphonium cation;
TT: Tocotrienols; Vit-E: Vitamin-E.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GC and JZ worked closely at all stages of the study and conducted most of
the experiments; DMM conducted the in vivo work. ACM carried out and
analyzed the pathology work. JJ synthesized the compounds tested in the
study. MBD provided some of the cell lines tested and contributed to
writing the manuscript. BK and GC conceived of the study, participated in its
design, and wrote the manuscript. All authors were involved in drafting,
revising and approving the final manuscript.
Acknowledgements
This study was supported by the National Institutes of Health (grant number
R01 CA152810). We also acknowledge the use of the mass spectrometer in
the MCW Cancer Center Bioenergetic Shared Resource.
Author details
1Free Radical Research Center and Department of Biophysics, Medical
College of Wisconsin, Milwaukee, WI, USA. 2Department of Pathology,
Medical College of Wisconsin, Milwaukee, WI, USA. 3Department of
Microbiology and Molecular Genetics, Medical College of Wisconsin,
Milwaukee, WI, USA.
Received: 11 April 2013 Accepted: 7 June 2013
Published: 13 June 2013
References
1. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond.
Cell 2008, 134:703–707.
2. Barger JF, Plas DR: Balancing biosynthesis and bioenergetics: metabolic
programs in oncogenesis. Endocr Relat Cancer 2010, 17:R287–R304.
3. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the
Warburg effect: the metabolic requirements of cell proliferation.
Science 2009, 324:1029–1033.
4. Cheng G, Zielonka J, Dranka BP, McAllister D, Mackinnon AC Jr, Joseph J,
Kalyanaraman B: Mitochondria-targeted drugs synergize with 2-deoxyglucose
to trigger breast cancer cell death. Cancer Res 2012, 72:2634–2644.
5. Beckham TH, Lu P, Jones EE, Marrison T, Lewis CS, Cheng JC, Ramshesh VK,
Beeson G, Beeson CC, Drake RR, Bielawska A, Bielawski J, Szulc ZM,
Ogretmen B, Norris JS, Liu X: LCL124, a cationic analog of ceramide,
selectively induces pancreatic cancer cell death by accumulating in
mitochondria. J Pharmacol Exp Ther 2013, 344:167–178.
6. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ: Cancer
pharmacogenomics: strategies and challenges. Nat Rev Genet 2013, 14:23–34.
Cheng et al. BMC Cancer 2013, 13:285 Page 14 of 14
http://www.biomedcentral.com/1471-2407/13/2857. Smith RA, Hartley RC, Murphy MP: Mitochondria-targeted small molecule
therapeutics and probes. Antioxid Redox Signal 2011, 15:3021–3038.
8. Millard M, Pathania D, Shabaik Y, Taheri L, Deng J, Neamati N: Preclinical
evaluation of novel triphenylphosphonium salts with broad-spectrum
activity. PLoS One 2010, 5:e13131. doi:10.1371/journal.pone.0013131.
9. Ju J, Picinich SC, Yang Z, Zhao Y, Suh N, Kong AN, Yang CS: Cancer-preventive
activities of tocopherols and tocotrienols. Carcinogenesis 2010, 31:533–542.
10. Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A,
Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Krishnan
BB: {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them
to gemcitabine treatment by modulating the inflammatory
microenvironment. Cancer Res 2010, 70:8695–8705.
11. Li GX, Lee MJ, Liu AB, Yang Z, Lin Y, Shih WJ, Yang CS: delta-tocopherol is
more active than alpha - or gamma -tocopherol in inhibiting lung
tumorigenesis in vivo. Cancer Prev Res (Phila) 2011, 4:404–413.
12. Shah SJ, Sylvester PW: Gamma-tocotrienol inhibits neoplastic mammary
epithelial cell proliferation by decreasing Akt and nuclear factor kappaB
activity. Exp Biol Med (Maywood) 2005, 230:235–241.
13. Azzi A, Ricciarelli R, Zingg JM: Non-antioxidant molecular functions of
alpha-tocopherol (vitamin E). FEBS Lett 2002, 519:8–10.
14. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K,
Salvatore BA, Ralph SJ: Vitamin E analogs, a novel group of “mitocans,” as
anticancer agents: the importance of being redox-silent. Mol Pharmacol 2007,
71:1185–1199.
15. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M,
Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, Goodwin J, Brunk UT,
Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, Neuzil J: Suppression
of tumor growth in vivo by the mitocan alpha-tocopheryl succinate
requires respiratory complex II. Clin Cancer Res 2009, 15:1593–1600.
16. Dong LF, Jameson VJ, Tilly D, Cerny J, Mahdavian E, Marin-Hernandez A,
Hernandez-Esquivel L, Rodriguez-Enriquez S, Stursa J, Witting PK, Stantic B,
Rohlena J, Truksa J, Kluckova K, Dyason JC, Ledvina M, Salvatore BA,
Moreno-Sánchez R, Coster MJ, Ralph SJ, Smith RA, Neuzil J: Mitochondrial
targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer
activity via mitochondrial complex II. J Biol Chem 2011, 286:3717–3728.
17. Wang F, Ogasawara MA, Huang P: Small mitochondria-targeting
molecules as anti-cancer agents. Mol Aspects Med 2010, 31:75–92.
18. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph
J, Kalyanaraman B: Supplementation of endothelial cells with mitochondria-
targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake,
oxidative damage, and apoptosis. J Biol Chem 2004, 279:37575–37587.
19. Holliday DL, Speirs V: Choosing the right cell line for breast cancer
research. Breast Cancer Res 2011, 13:215.
20. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C,
Guise TA, Massague J: A multigenic program mediating breast cancer
metastasis to bone. Cancer Cell 2003, 3:537–549.
21. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB,
Gerald WL, Massague J: Genes that mediate breast cancer metastasis to
lung. Nature 2005, 436:518–524.
22. Wendt MK, Cooper AN, Dwinell MB: Epigenetic silencing of CXCL12
increases the metastatic potential of mammary carcinoma cells.
Oncogene 2008, 27:1461–1471.
23. Fischer EG, Stingl A, Kirkpatrick CJ: Migration assay for endothelial cells in
multiwells. Application to studies on the effect of opioids. J Immunol
Methods 1990, 128:235–239.
24. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic
assay of cells in vitro. Nat Protoc 2006, 1:2315–2319.
25. Dranka BP, Hill BG, Rley-Usmar VM: Mitochondrial reserve capacity in
endothelial cells: the impact of nitric oxide and reactive oxygen species.
Free Radic Biol Med 2010, 48:905–914.
26. Nicholls DG, Rley-Usmar VM, Wu M, Jensen PB, Rogers GW, Ferrick DA:
Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp
2010, 46:e2511. doi:10.3791/2511.
27. Nadakavukaren KK, Nadakavukaren JJ, Chen LB: Increased rhodamine 123
uptake by carcinoma cells. Cancer Res 1985, 45:6093–6099.
28. Kurtoglu M, Lampidis TJ: From delocalized lipophilic cations to hypoxia:
blocking tumor cell mitochondrial function leads to therapeutic gain
with glycolytic inhibitors. Mol Nutr Food Res 2009, 53:68–75.
29. Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren
KK, Shepherd EL, Chen LB: Unusual retention of rhodamine 123 bymitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 1982,
79:5292–5296.
30. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’Sullivan JD, Fung V, Smith
RA, Murphy MP, Taylor KM: A double-blind, placebo-controlled study to
assess the mitochondria-targeted antioxidant MitoQ as a disease-
modifying therapy in Parkinson’s disease. Mov Disord 2010, 25:1670–1674.
31. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer
treatment. Oncogene 2006, 25:4633–4646.
32. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H,
Cinalli RM, Alavi A, Rudin CM, Thompson CB: Akt stimulates aerobic
glycolysis in cancer cells. Cancer Res 2004, 64:3892–3899.
33. Dang CV: Links between metabolism and cancer. Genes Dev 2012,
26:877–890.
34. Marin-Hernandez A, Gallardo-Perez JC, Rodriguez-Enriquez S, Encalada R,
Moreno-Sanchez R, Saavedra E: Modeling cancer glycolysis. Biochim
Biophys Acta 1807, 2011:755–767.
35. Fan Y, Dickman KG, Zong WX: Akt and c-Myc differentially activate
cellular metabolic programs and prime cells to bioenergetic inhibition.
J Biol Chem 2010, 285:7324–7333.
36. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev
Cancer 2011, 11:85–95.
37. Pathania D, Millard M, Neamati N: Opportunities in discovery and delivery
of anticancer drugs targeting mitochondria and cancer cell metabolism.
Adv Drug Deliv Rev 2009, 61:1250–1275.
38. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M,
Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS: Mitochondrial
metabolism and ROS generation are essential for Kras-mediated
tumorigenicity. Proc Natl Acad Sci USA 2010, 107:8788–8793.
39. Wei S, Kulp SK, Chen CS: Energy restriction as an antitumor target of
thiazolidinediones. J Biol Chem 2010, 285:9780–9791.
40. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV: The mechanism of
action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr
2001, 33:481–491.
41. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher
H, Widger W, Ellis LM, Weihua Z: Intracellular ATP levels are a pivotal
determinant of chemoresistance in colon cancer cells. Cancer Res 2012,
72:304–314.
42. Prochazka L, Koudelka S, Dong LF, Stursa J, Goodwin J, Neca J, Slavik J, Ciganek
M, Masek J, Kluckova K, Nguyen M, Turanek J, Neuzil J: Mitochondrial targeting
overcomes ABCA1-dependent resistance of lung carcinoma to alpha-
tocopheryl succinate. Apoptosis 2013, 18:286–299.
43. Lopes MA, Meisel A, Carvalho FD, Bastos ML: Neuronal nitric oxide
synthase is a key factor in doxorubicin-induced toxicity to rat-isolated
cortical neurons. Neurotox Res 2011, 19:14–22.
44. Gianni L, Salvatorelli E, Minotti G: Anthracycline cardiotoxicity in breast
cancer patients: synergism with trastuzumab and taxanes. Cardiovasc
Toxicol 2007, 7:67–71.
45. Mao G, Kraus GA, Kim I, Spurlock ME, Bailey TB, Beitz DC: Effect of a
mitochondria-targeted vitamin E derivative on mitochondrial alteration and
systemic oxidative stress in mice. Br J Nutr 2011, 106:87–95.
46. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA,
Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B:
Doxorubicin inactivates myocardial cytochrome c oxidase in rats:
cardioprotection by Mito-Q. Biophys J 2009, 96:1388–1398.
47. Mukhopadhyay P, Horvath B, Zsengeller Z, Zielonka J, Tanchian G, Holovac
E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B,
Pacher P: Mitochondrial-targeted antioxidants represent a promising
approach for prevention of cisplatin-induced nephropathy. Free Radic Biol
Med 2012, 52:497–506.
48. Gohil VM, Sheth SA, Nilsson R, Wojtovich AP, Lee JH, Perocchi F, Chen W,
Clish CB, Ayata C, Brookes PS, Mootha VK: Nutrient-sensitized screening for
drugs that shift energy metabolism from mitochondrial respiration to
glycolysis. Nat Biotechnol 2010, 28:249–255.
49. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan
MC: Potentiation of chemotherapeutic drugs by energy metabolism
inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123:476–483.
doi:10.1186/1471-2407-13-285
Cite this article as: Cheng et al.: Mitochondria-targeted vitamin E
analogs inhibit breast cancer cell energy metabolism and promote cell
death. BMC Cancer 2013 13:285.
